Browsing Clinical Studies by author "Pearson, Alex"

Now showing items 1-3 of 3

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.

Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-08)

<h4>Background</h4>Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of ...
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.

Chopra, N; Tovey, H; Pearson, A; Cutts, R; Toms, C; Proszek, P; Hubank, M; Dowsett, M; Dodson, A; Daley, F; Kriplani, D; Gevensleben, H; Davies, HR; Degasperi, A; Roylance, R; Chan, S; Tutt, A; Skene, A; Evans, A; Bliss, JM; Nik-Zainal, S; Turner, NC (2020-05-29)

Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO ...
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.

Pascual, J; Lim, JSJ; Macpherson, IR; Armstrong, AC; Ring, A; Okines, AFC; Cutts, RJ; Herrera-Abreu, MT; Garcia-Murillas, I; Pearson, A; Hrebien, S; Gevensleben, H; Proszek, PZ; Hubank, M; Hills, M; King, J; Parmar, M; Prout, T; Finneran, L; Malia, J; Swales, KE; Ruddle, R; Raynaud, FI; Turner, A; Hall, E; Yap, TA; Lopez, JS; Turner, NC (2020-09-21)

Cyclin-dependent kinase 4/6 (CDK4/6) and PI3K inhibitors synergize in <i>PIK3CA</i>-mutant ER-positive HER2-negative breast cancer models. We conducted a phase Ib trial investigating the safety and efficacy of doublet ...

Publications Repository

Publications Repository

Browsing Clinical Studies by author "Pearson, Alex"

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.

Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.

Browsing Clinical Studies by author "Pearson, Alex"

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. ﻿

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. ﻿

Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. ﻿

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.

Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.